BSD Medical is Now Pyrexar Medical

The complete line of BSD Hyperthermia products are availble thru Pyrexar Medical

Pyrexar traveled to Kuwait to address physicians at the Kuwait Cancer Control Center (KCCC). Founded in 1968, the KCCC is affiliated with the Kuwait Ministry of Health and is dedicated to provide Cancer Care across the State of Kuwait. The center utilizes all available resources to serve cancer patients with a wide selection of treatment modalities. We hope to see hyperthermia as a featured treatment option this year.

Ahmed El Ghamry, Business Unit Manager, MedVision | Mark Falkowski, CEO - Pyrexar Medical | Ali Rabie, Senior Product Specialist, MedVision at the GUG Exhibit

International Conference on Genitourinary & Gynecological Cancers - Kuwait Conference April 14-16

Salwa Sabah Al-Ahmad presentation hall at the Marina Hotel

Salwa Sabah Al-Ahmad Theater & Hall in Kuwait City

previous arrow
next arrow
ArrowArrow
Slider


While there, we joined our Middle East distribution partner Medvision at their booth at the GUG-KC (Genitourinary & Gyneclogical Cancers Kuwait Conference) held at the Salwa Sabah Al-Ahmad Theatre. The booth was visited by Dr. Mustafa Redah, Co-Minister of Health; Dr. Kholoud Al Ali, head of the KCCC; and Dr. Al Saleh, head of Radiation Oncology at KCCC. The group was very impressed by the new technologies Pyrexar has pioneered and the benefits of hyperthermia in the treatment of cancer.

A special thanks to the Medvision team for their generous hospitality during the event.

I wanted to share this recent communication from our colleagues at Sennewald Medizintechnik.


There are only a few weeks to go until the ESHO Meeting in Berlin and it is not too late to register via ESHO Congress website, if you have not already done so. We asked Dr. Pirus Ghadjar (ESHO 2018 Congress Organization) to outline the main highlights of the event.

Since the hyperthermia department at the Charité Universitätsmedizin in Berlin is one of the nine centers that contributed to the long-term results of the EORTC 62961-ESHO 95 trial recently published in JAMA Oncology Journal, we also asked Dr. Ghadjar some

more detailed questions about the trial. You will find his answers below.The hyperthermia systems used in the trial were provided by BSD/Pyrexar Medical, so we are pleased to point out that as a Diamond Sponsor of the ESHO Meeting, we are holding a Lunch Symposium on May 17 on “Pyrexar Innovations 2018”.

DR. GHADJAR  ABOUT -  ESHO 2018

Ghadjar.297x337JPGDr. Ghadjar, could you please summarize the highlights of the ESHO 2018 program?
I am pleased to say that the program of this year’s ESHO is very interesting and includes several highlights. For instance, the "abdominal tumor" session providing information on the latest treatment for pancreatic cancer and liver tumors and the use of hyperthermia to improve current treatment standards for abdominal tumors. The session on "MR-guided thermal therapies and applications" will summarize recent developments in MR thermometry as well as MR-based heat treatments. Another highlight -- among others -- will be the session on "Immune effects of hyperthermia and novel drug combinations" where the combination of hyperthermia and checkpoint inhibitors will be discussed.

The 2018 ESHO program also includes a one-day nurse/radiation therapist symposium, as well as a Patient Information Day, which will be held in German.

INTERVIEW DR. GHADJAR JAMA ONCOLOGY JOURNAL PUBLICATION

1. The EORTC 62961-ESHO 95 Trial was completed in November 2006. Why is JAMA Oncology only reporting now and what is the significance?

Long term data of the EORTC 62961-ESHO 95 trial comparing neoadjuvant chemotherapy vs. neoadjuvant regional hyperthermia plus chemotherapy for patients with localized high-risk soft tissue sarcoma was published by Issels et al. in February 2018 based on a median follow-up of 11.3 years. The recruitment of the total number of 341 patients was conducted from July 1997 to November 2006. The database for this analysis was closed in December 2014. The long follow-up duration is necessary to analyze potential differences in the secondary trial endpoint of overall survival. The significance of the results is that the addition of regional hyperthermia did not only improve local progression-free survival but also significantly improved overall survival as compared to neoadjuvant chemotherapy alone.

2. But why has it taken so long to publish the results?

Issels et al. closely analyzed their data after the database was closed. Due to the unique and convincing data, the manuscript was then submitted to high-impact medical journals and the process of manuscript review, re-submission and revision took time until the manuscript was accepted for publication by JAMA Oncology.

3. Is it true the study was prematurely halted? Were there negative results?

No, the predefined analysis plan as stated in the trial protocol was followed. The early trial results were published in Lancet Oncology in 2010, reporting that the primary trial endpoint local progression-free survival was significantly improved by neoadjuvant regional hyperthermia plus chemotherapy vs. neoadjuvant chemotherapy alone based on a median follow-up of 34 months. As the primary trial endpoint was significantly improved (as far back as 2010) the trial had to be regarded as a positive one. In 2010 the follow-up duration was not sufficient to detect potential differences in overall survival. Eight years later this has changed, and a significant overall survival benefit could be detected in favor of regional hyperthermia.

>Click here to read the rest of the interview regarding the JAMA Oncology publication

Infografik SSTS

Great opportunity to view the International Journal of Hyperthermia for free. Volume 34, Issue 2 has been set to "free access" until May 30th, 2018.

Issue highlights editorials and reviews on the role of thermal therapy with infectious diseases.  If you want access to all of the issues of the IJH, the most cost efficient way to become an STM or ESHO member.  Membership provides additional cost benefits to the corresponding conferences, but it also helps build and promote hyperthermia research and treatment expansion throught the world.

IJOH DEC2014

The Journal of the American Medical Association (JAMA) just published a 10 year patient follow-up to a phase III clinical study on a Soft Tissue Sarcoma Study.

STS Infographic thumb


With Invited Commentary - Technological Advances, Biologic Rationales, and the Associated Success of Chemotherapy With Hyperthermia in Improved Outcomes in Patients With Sarcoma by Mark W. Dewhirst, DVM, PhD; David Kirsch, MD, PhD

Under the organization of the European Society of Hyperthermic Oncology the study was conducted in 9 centers located in Germany, Norway, Austria and the United States using the BSD-2000 Deep Regional Hyperthermia System. This study enrolled 365 soft tissue sarcoma patients (18-70 years old) that were matched and entered into a double blind study. One group received neoadjuvant chemotherapy consisting of doxorubicin, ifosfamide, and etoposide [CT] treatment and the other group received the same chemotherapy along with a course of hyperthermia [HT].

For non-clinicians, we have done our best to provide the salient points in the above info-graphic. The full article can be found on the JAMA website here.

We feel that the results are astonishing. The HEADLINE: chemotherapy plus hyperthermia equals better results and extended life. #heatmatters